Cangrelor: a review on its mechanism of action and clinical development

References

• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK; Clopidogrel in Unstable Angina to prevent Recurrent Events (CURE) Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N. Engl. J. Med.345(7), 494–502 (2001).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al.; CLARITY-TIMI 28 Investigators. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12), 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al.; COMMIT (Clopidogrel and Metoprolol in Myocardial Infarction Trial) Collaborative Group. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ et al.; Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet358(9281), 527–533 (2001).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT 3rd et al.; CREDO Investigators. Clopidogrel for the Reduction of Events During Observation. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA288(19), 2411–2420 (2002).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al.; Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA294(10), 1224–1232 (2005).
   PubMed Web of Science ®Google Scholar
• Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. J. Am. Coll. Cardiol.50(7), E1–E157 (2007).
   Google Scholar
• King SB 3rd, Smith SC Jr, Hirshfeld JW Jr et al. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice guidelines. J. Am. Coll. Cardiol.51(2), 172–209 (2008).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. Variability in responsiveness to oral antiplatelet therapy. Am. J. Cardiol.103(3 Suppl.), A27–A34 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Suryadevara S, Capranzano P, Zenni MZ, Guzman LA, Bass TA. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc. Interv.73(1), 1–14 (2009).
   Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J. Am. Coll. Cardiol.49(14), 1505–1516 (2007).
   PubMed Web of Science ®Google Scholar
• Ferreiro JL, Angiolillo DJ. Clopidogrel response variability: current status and future directions. Thromb. Haemost.102(1), 7–14 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ. ADP receptor antagonism: what’s in the pipeline? Am. J. Cardiovasc. Drugs7(6), 423–432 (2007).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bhatt DL, Gurbel PA, Jennings LK. Advances in antiplatelet therapy: agents in clinical development. Am. J. Cardiol.103(3 Suppl.), A40–A51 (2009).
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Guzman LA. Clinical overview of promising nonthienopyridine antiplatelet agents. Am. Heart J.156(2 Suppl.), S23–S28 (2008).
   Web of Science ®Google Scholar
• Storey RF, Newby LJ, Heptinstall S. Effects of P2Y1 and P2Y12 receptor antagonists on platelet aggregation induced by different agonists in human whole blood. Platelets12(7), 443–447 (2001).
   PubMed Web of Science ®Google Scholar
• Gachet C. ADP receptors of platelets and their inhibition. Thromb. Haemost.86(1), 222–232 (2001).
   PubMed Web of Science ®Google Scholar
• Dorsam RT, Kunapuli SP. Central role of the P2Y12 receptor in platelet activation. J. Clin. Invest.113(3), 340–345 (2004).
   PubMed Web of Science ®Google Scholar
• Mega JL, Close SL, Wiviott SD et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N. Engl. J. Med.360(4), 354–362 (2009).
   PubMed Web of Science ®Google Scholar
• Simon T, Verstuyft C, Mary-Krause M et al.; French Registry of Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) Investigators. Genetic determinants of response to clopidogrel and cardiovascular events. N. Engl. J. Med.360(4), 363–375 (2009).
   PubMed Web of Science ®Google Scholar
• Marin F, Gonzalez-Conejero R, Capranzano P, Bass TA, Roldan V, Angiolillo DJ. Pharmacogenetics in cardiovascular antithrombotic therapy. J. Am. Coll. Cardiol.54(12), 1041–1057 (2009).
   PubMed Web of Science ®Google Scholar
• Kahner BN, Shankar H, Murugappan S, Prasad GL, Kunapuli SP. Nucleotide receptor signaling in platelets. J. Thromb. Haemost.4(11), 2317–2326 (2006).
   PubMed Web of Science ®Google Scholar
• Hechler B, Vigne P, Léon C, Breittmayer JP, Gachet C, Frelin C. ATP derivatives are antagonists of the P2Y1 receptor: similarities to the platelet ADP receptor. Mol. Pharmacol.53(4), 727–733 (1998).
   PubMed Web of Science ®Google Scholar
• Ingall AH, Dixon J, Bailey A et al. Antagonists of the platelet P2T receptor: a novel approach to antithrombotic therapy. J. Med. Chem.42(2), 213–220 (1999).
   PubMed Web of Science ®Google Scholar
• Storey RF, Oldroyd KG, Wilcox RG. Open multicentre study of the P2T receptor antagonist AR-C69931MX assessing safety, tolerability and activity in patients with acute coronary syndromes. Thromb. Haemost.85(3), 401–407 (2001).
   PubMed Web of Science ®Google Scholar
• Huang J, Driscoll EM, Gonzales ML, Park AM, Lucchesi BR. Prevention of arterial thrombosis by intravenously administered platelet P2T receptor antagonist AR-C69931MX in a canine model. J. Pharmacol. Exp. Ther.295(2), 492–499 (2000).
   PubMed Web of Science ®Google Scholar
• van Gestel MA, Heemskerk JW, Slaaf DW, Heijnen VV, Reneman RS, oude Egbrink MG. In vivo blockade of platelet ADP receptor P2Y12 reduces embolus and thrombus formation but not thrombus stability. Arterioscler. Thromb. Vasc. Biol.23(3), 518–523 (2003).
   PubMed Web of Science ®Google Scholar
• van Giezen JJ, Humphries RG. Preclinical and clinical studies with selective reversible direct P2Y12 antagonists. Semin. Thromb. Hemost.31(2), 195–204 (2005).
   PubMed Web of Science ®Google Scholar
• Nassim MA, Sanderson JB, Clarke C et al. Investigation of the novel P2T receptor antagonist AR-C69931MX on ex vivo adenosine diphosphate-induced platelet aggregation and bleeding time in healthy volunteers. J. Am. Coll. Cardiol.33(2 Suppl. A), A255 (1999).
   Web of Science ®Google Scholar
• Jarvis GE, Nassim MA, Humphries RG et al. The P2T antagonist Ar-C69931MX is a more effective inhibitor of ADP-induced platelet aggregation than clopidogrel. Blood94(Suppl. 1), A22 (1999).
   Google Scholar
• Dovlatova NL, Jakubowski JA, Sugidachi A, Heptinstall S. The reversible P2Y antagonist cangrelor influences the ability of the active metabolites of clopidogrel and prasugrel to produce irreversible inhibition of platelet function. J. Thromb. Haemost.6(7), 1153–1159 (2008).
   PubMed Web of Science ®Google Scholar
• Jacobsson F, Swahn E, Wallentin L, Ellborg M. Safety profile and tolerability of intravenous AR-C69931MX, a new antiplatelet drug, in unstable angina pectoris and non-Q-wave myocardial infarction. Clin. Ther.24(5), 752–765 (2002).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Ohman EM, Gibson CM et al. Preliminary experience with intravenous P2Y12 platelet receptor inhibition as an adjunct to reduced-dose alteplase during acute myocardial infarction: results of the Safety, Tolerability and Effect on Patency in Acute Myocardial Infarction (STEP-AMI) angiographic trial. Am. Heart J.154(4), 702–709 (2007).
   PubMed Web of Science ®Google Scholar
• Greenbaum AB, Grines CL, Bittl JA et al. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Am. Heart J.151(3), 689.E1–689.E10 (2006).
   PubMed Web of Science ®Google Scholar
• Storey RF, Wilcox RG, Heptinstall S. Comparison of the pharmacodynamic effects of the platelet ADP receptor antagonists clopidogrel and AR-C69931MX in patients with ischaemic heart disease. Platelets13(7), 407–413 (2002).
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Oh JJ, Oestreich JH, Ferraris S, Charnigo R, Akers WS. Transitioning patients from cangrelor to clopidogrel: pharmacodynamic evidence of a competitive effect. Thromb. Res.121(4), 527–534 (2008).
   PubMed Web of Science ®Google Scholar